Screener
Beam Therapeutics BEAM EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Beam Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
FAQ
- What is Beam Therapeutics's EBITDA margin?
- Beam Therapeutics (BEAM) reported EBITDA margin of -212.9% in Q1 2026.
- How has Beam Therapeutics's EBITDA margin changed year-over-year?
- Beam Therapeutics's EBITDA margin increased by 66.9% year-over-year, from -642.8% to -212.9%.
- What is the long-term trend for Beam Therapeutics's EBITDA margin?
- Over 4 years (2020 to 2025), Beam Therapeutics's EBITDA margin has grown at a -85.2% compound annual growth rate (CAGR), from -533,437.5% to -258.6%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Beam Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude